Robot model
Versius
CMR Surgical (founded 2014, Cambridge, UK; private) makes Versius, the genuine challenger among surgical-robot startups and the one that has clearly crossed…
- Manufacturer
- CMR Surgical
- Form factor
- surgical
- Maturity
- commercial
- Lifecycle
- active
- Deployments
- 2
Overview
CMR Surgical (founded 2014, Cambridge, UK; private) makes Versius, the genuine challenger among surgical-robot startups and the one that has clearly crossed the regulatory gating event. Versius is a modular multi-arm teleoperated soft-tissue robot that is heavily software-driven, capturing telematic, video, and outcome data. It received US FDA De Novo marketing authorization in October 2024, the first such authorization for a multi-port soft-tissue general-surgery robot, followed by an FDA 510(k) clearance for the next-generation Versius Plus on December 18, 2025 with US commercialization on track for 2026, and a pending gynecology 510(k) submitted on April 29, 2026; it has long been CE-marked and commercial across Europe, Latin America, the Africa-Middle-East region, and Australia, with more than 40,000 procedures completed outside the US by company reporting. The registry records it at commercial maturity with an active lifecycle. An important current-state correction: the 2021 roughly $3 billion SoftBank-led valuation story is frozen in time, the company went through real restructuring in 2023 with about 350 redundancies, and it was recapitalized with more than $200 million in April 2025, while reported figures of a roughly $3.1 billion 2025 valuation and a potential $4 billion sale are rumor-tier aggregator claims that are not registered. On AI substance the shipped reality is a data-capture and analytics ecosystem with the surgeon in full control; the physical-AI framing is forward-looking, anchored in a March 2026 NVIDIA IGX Thor partnership to evaluate AI for a future Versius, with no autonomous or AI-assisted intraoperative feature cleared or shipped.
Verified vs. claimed
- Maturity stage
- commercial(Commercially deployed with revenue-generating operations.)
- Verified deployments
- 2 deployments on file
- Sources on file
- 5 sources, view all
Key facts
Form factor
Procedures completed
FDA authorization
Recapitalization
Restructuring
Specs
Arms
Notes
Products
Form Factor
Fda clearance
Clearance body
Procedure types
Data & sources
Press releases
2
News coverage
1
Web sources
2
5 sources backing this record.View all →
Availability and pricing
- Availability
- Not sold (internal use)
- Price
- $750K to $1M (analyst estimate)as of 2024-01-01
- Units in field
- Not disclosed
- Sales model
- Not disclosed
- Lead time
- Not disclosed
Pricing
One-time purchase
$750,000 - $1,000,000 USDanalyst estimateas of 2024-01-01
Source: How Much is a Surgical Robot? — R2 Surgical industry pricing guide
Price status: actual-sale-price = real published price at time of sale; manufacturer-target = vendor target, not yet realized; analyst-estimate = third-party projection, not a vendor figure; not-announced = no price on record.
Prices verified as of Jan 1, 2024
Deployments (2)
- Versius at Indiaoperational
Versius has been installed across approximately 10 or more hospitals in India, including Apollo and Aster facilities, following CDSCO approval for laparoscopic surgery.
- Versius at United Kingdomoperational
Versius surgical robot systems have been deployed at multiple UK NHS hospitals, including Royal Papworth Hospital for thoracic surgery, Addenbrooke's Hospital, and Milton Keynes University Hospital, the latter of which…
Versius on the deployment map
Where Versius is verified operating. Explore the deployment map by place and type.
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Verified media addedVerifiedJun 5, 2026
CMR Versius Plus
- Verified media addedVerifiedJun 5, 2026
Versius robotic cholecystectomy
- Verified media addedVerifiedJun 4, 2026
Introducing Versius
- Record createdJun 3, 2026
Added to the verified registry
- Price point recorded: $750,000-$1,000,000Jan 1, 2024
Analyst estimate
Deployment-verified media (3)
CMR Surgical's overview of Versius Plus, framed around freedom of access by design. The system is surgeon-teleoperated, never autonomous.
From deployment: India
CMR Surgical's footage of a robotic cholecystectomy performed on Versius at Manchester Royal Infirmary. Surgeon-teleoperated, never autonomous.
From deployment: India
CMR Surgical's introduction of its Versius surgical robotic system. A surgeon teleoperates Versius from a console; it is never autonomous.
From deployment: India
Supply chain (1)
Compute / semiconductor
- NVIDIANVIDIA IGX Thor industrial AI compute platform -- adopted as early-adopter evaluation for next-generation Versius surgical robotic system; IGX Thor delivers up to 5,581 FP4 TFLOPS AI compute with 400 GBe connectivity for real-time surgical AI inference and decision support; CMR Surgical also contributed anonymized surgical data to NVIDIA Isaac GRooT-H vision-language-action model for healthcare roboticssuppliesannounced
Suppliers appear here when verified with at least two strong sources (maker-official / IR / regulatory / standards-body / verified tier-2). Sources are append-only; corrections add new sources rather than rewrite history.
Regulatory filings (3)
- fda_510kfda 510k · us_fdacleared
- fda_de_novofda de novo · us_fdacleared2024-10-01
Applicant: CMR Surgical
- DEN230078fda de novo · us_fdagranted2023-11-21
Applicant: CMR Surgical
Safety record
No incidents on record for Versius.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Sources (5)
- https://www.globenewswire.com/news-release/2024/10/15/cmr-surgical-versius-fda-de-novo
- https://www.therobotreport.com/cmr-surgical-receives-fda-clearance-for-versius-plus-surgical-robot/
- https://www.massdevice.com/cmr-surgical-200-million-funding/
- https://www.globenewswire.com/news-release/2026/03/17/cmr-surgical-nvidia-igx-thor
- https://www.cambridgeindependent.co.uk/news/cmr-surgical-redundancies
Compare Versius
Common questions
- What is Versius?
- CMR Surgical (founded 2014, Cambridge, UK; private) makes Versius, the genuine challenger among surgical-robot startups and the one that has clearly crossed the regulatory gating event. Versius is a modular multi-arm teleoperated soft-tissue robot that is heavily software-driven, capturing telematic, video, and outcome data. It received US FDA De Novo marketing authorization in October 2024, the first such authorization for a multi-port soft-tissue general-surgery robot, followed by an FDA 510(k) clearance for the next-generation Versius Plus on December 18, 2025 with US commercialization on track for 2026, and a pending gynecology 510(k) submitted on April 29, 2026; it has long been CE-marked and commercial across Europe, Latin America, the Africa-Middle-East region, and Australia, with more than 40,000 procedures completed outside the US by company reporting. The registry records it at commercial maturity with an active lifecycle. An important current-state correction: the 2021 roughly $3 billion SoftBank-led valuation story is frozen in time, the company went through real restructuring in 2023 with about 350 redundancies, and it was recapitalized with more than $200 million in April 2025, while reported figures of a roughly $3.1 billion 2025 valuation and a potential $4 billion sale are rumor-tier aggregator claims that are not registered. On AI substance the shipped reality is a data-capture and analytics ecosystem with the surgeon in full control; the physical-AI framing is forward-looking, anchored in a March 2026 NVIDIA IGX Thor partnership to evaluate AI for a future Versius, with no autonomous or AI-assisted intraoperative feature cleared or shipped.
- How much does Versius cost?
- Versius is listed at $750,000 to $1,000,000 on the DEPLOY registry. This is an analyst estimate, not an official price.
- Is Versius actually deployed in the real world?
- Yes. Versius is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
- Is Versius autonomous or teleoperated?
- Not verified as fully autonomous. Versius's capabilities on the DEPLOY registry are recorded as teleoperated-assisted, demonstrated-only, or vendor claims (Assists surgery), not independently confirmed to run without a human in the loop.
- Who makes Versius?
- Versius is made by CMR Surgical, based in Cambridge, United Kingdom, founded in 2014.
- Where is Versius deployed?
- 2 verified deployments of Versius are on the DEPLOY registry, including at India, United Kingdom.
- Can you buy Versius?
- Versius is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
- Is Versius FDA cleared?
- Versius has 3 regulatory records on the DEPLOY registry: FDA 510(k) clearance, cleared; FDA De Novo authorization, cleared; FDA De Novo authorization (DEN230078), granted. See the Regulatory filings section for each agency source.
- What are alternatives to Versius?
- On the DEPLOY registry, comparable surgical robots to Versius include Toumai, da Vinci (and Ion), Epione, Hugo RAS.
- How does Versius compare to Toumai?
- Versius and Toumai (MicroPort MedBot · 8 deployments) are both surgical robots on the DEPLOY registry. Versius has 2 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
- Is Versius a top surgical?
- On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Versius ranks in roughly the top 17% of surgical models tracked by the registry.
- What is Versius's maturity stage?
- Versius is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
- Is Versius safe?
- Versius has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
- How does the CMR Versius compare to da Vinci?
- The CMR Versius is a modular and portable surgical robot designed to make minimal access surgery more accessible. A da Vinci system costs $1.5M to $2.5M depending on configuration, plus annual maintenance. Versius is designed to be more portable and affordable than da Vinci, with a modular architecture that fits in smaller operating rooms.
Methodology: Verified · 5 sources (2 primary) · last reviewed 2026-07-12
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-07-12
Maturity + lifecycle
Maturity stage: commercial
Lifecycle: active
Architectural position
Cohort: surgical
Sources by quality tier
- 2
- primary-company-ir
- Company IR disclosure
- 2
- unclassified
- Unclassified source
- 1
- secondary-trade-publication
- Trade publication
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Versius.Recent coverage
Versius in third-party press
Attention vs reality over time
Media mentions per month (area) against verified deployment events (dots). A press spike over a flat deployment line is the hype gap, drawn over time.
In the press
Recent coverage mentioning Versius from third-party publications. Automatically surfaced; not part of the verified registry record.
CMR Surgical secures 510k clearance of Versius Plus robotic surgical system
CMR Surgical received FDA 510k clearance for its second-generation Versius Plus surgical robot for cholecystectomy procedures, paving the way for US commercial launch in 2026.…
FDA Clears New Robotic Platform for Gallbladder Surgery
CMR Surgicals Versius Plus received FDA 510(k) clearance for gallbladder surgery, on track for US commercialization in 2026.
CMR Raises 00M in Series D Funding for Versius Surgical Robots
CMR Surgical raised 00M in Series D funding to scale Versius, its minimally invasive surgical robot system.
Machine-readable surfaces
- Markdown mirror: /models/cmr-versius.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/models/34aec096-0484-4591-b8c1-f65bd183344f
- Revision history: /models/cmr-versius/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Buyer-facing pricing: deploy.report/price/cmr-versius
Video
Reality vs attention
Versius draws attention at the 68th percentile but verifies reality at the 71st percentile among surgical robots. Hype Gap -2.6, 14th widest among surgical robots.
6-month trend
Analysis
Thin deployment record; scale validation still in progress.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 19, 2026